Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Valneva ( (VALN) ) has shared an announcement.
On January 9, 2026, Valneva announced that its management team, including CEO Thomas Lingelbach and CFO Peter Bühler, will hold one-on-one meetings with existing shareholders and other institutional specialist investors during the 44th Annual J.P. Morgan Healthcare Conference, taking place January 12–14, 2026, in San Francisco. The executives plan to discuss upcoming catalysts from Valneva’s clinical pipeline—most notably a pivotal data readout for its Lyme disease vaccine expected in the first half of 2026—alongside the performance of its commercial vaccine portfolio, signaling an effort to strengthen investor engagement and highlight the company’s late-stage assets and growth prospects.
The most recent analyst rating on (VALN) stock is a Hold with a $9.50 price target. To see the full list of analyst forecasts on Valneva stock, see the VALN Stock Forecast page.
Spark’s Take on VALN Stock
According to Spark, TipRanks’ AI Analyst, VALN is a Neutral.
Valneva’s overall stock score reflects significant financial challenges, including negative profitability and cash flow issues. While technical indicators show neutral momentum, and the earnings call highlighted some positive developments, the company’s high leverage and ongoing losses weigh heavily on the score. Promising clinical advancements provide potential for future growth but are not enough to offset current financial concerns.
To see Spark’s full report on VALN stock, click here.
More about Valneva
Valneva SE is a specialty vaccine company that develops, manufactures and commercializes prophylactic vaccines for infectious diseases with unmet medical needs. Leveraging expertise across multiple vaccine modalities, the company focuses on first-, best- or only-in-class vaccine solutions and currently markets three proprietary travel vaccines. Its commercial revenues support a pipeline that includes the only Lyme disease vaccine candidate in advanced clinical development, partnered with Pfizer, as well as the world’s most clinically advanced tetravalent Shigella vaccine candidate and other programs targeting global public health threats.
Average Trading Volume: 24,667
Technical Sentiment Signal: Buy
Current Market Cap: $844M
Find detailed analytics on VALN stock on TipRanks’ Stock Analysis page.